Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin in Pancreatic Islet Auto-transplantation
NCT01967888Phase 3Completed
- Sponsor
- Dompé
- Start
- Feb 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in postpancreatectomy diabetes mellitus comparing Reparixin with Placebo (2 arms). Primary endpoint: Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation at 365 days. Started Feb 2014; status: completed.
02
Drugs
reparixin
03
Conditions
postpancreatectomy diabetes mellitus
Beyond the preview
Go deeper on NCT01967888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01967888.